BR112015002697A8 - uso de ligante de receptor de adenosina a3 (a3ar), ligante de a3ar, e, composição farmacêutica para tratar disfunção sexual em um indivíduo - Google Patents

uso de ligante de receptor de adenosina a3 (a3ar), ligante de a3ar, e, composição farmacêutica para tratar disfunção sexual em um indivíduo

Info

Publication number
BR112015002697A8
BR112015002697A8 BR112015002697A BR112015002697A BR112015002697A8 BR 112015002697 A8 BR112015002697 A8 BR 112015002697A8 BR 112015002697 A BR112015002697 A BR 112015002697A BR 112015002697 A BR112015002697 A BR 112015002697A BR 112015002697 A8 BR112015002697 A8 BR 112015002697A8
Authority
BR
Brazil
Prior art keywords
a3ar
binder
individual
pharmaceutical composition
sexual dysfunction
Prior art date
Application number
BR112015002697A
Other languages
English (en)
Other versions
BR112015002697A2 (pt
Inventor
Fishman Pnina
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of BR112015002697A2 publication Critical patent/BR112015002697A2/pt
Publication of BR112015002697A8 publication Critical patent/BR112015002697A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112015002697A 2012-08-09 2013-08-08 uso de ligante de receptor de adenosina a3 (a3ar), ligante de a3ar, e, composição farmacêutica para tratar disfunção sexual em um indivíduo BR112015002697A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL22138212 2012-08-09
IL22298812 2012-11-12
PCT/IL2013/050675 WO2014024195A1 (en) 2012-08-09 2013-08-08 A3 adenosine receptor ligands for use in treatment of a sexual dysfunction

Publications (2)

Publication Number Publication Date
BR112015002697A2 BR112015002697A2 (pt) 2017-10-31
BR112015002697A8 true BR112015002697A8 (pt) 2018-01-16

Family

ID=49003954

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015002697A BR112015002697A8 (pt) 2012-08-09 2013-08-08 uso de ligante de receptor de adenosina a3 (a3ar), ligante de a3ar, e, composição farmacêutica para tratar disfunção sexual em um indivíduo

Country Status (13)

Country Link
US (1) US9549943B2 (pt)
EP (2) EP3530273A3 (pt)
JP (1) JP6140825B2 (pt)
KR (1) KR101971762B1 (pt)
CN (1) CN104619323B (pt)
AU (1) AU2013301125B2 (pt)
BR (1) BR112015002697A8 (pt)
CA (1) CA2880753C (pt)
HK (1) HK1209342A1 (pt)
IL (1) IL237107B (pt)
MX (1) MX2015001644A (pt)
RU (1) RU2015105407A (pt)
WO (1) WO2014024195A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115779089A (zh) * 2022-11-28 2023-03-14 中国医学科学院肿瘤医院 用于治疗或改善雄性癌症及抑制其细胞系的药物的相关应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4788966A (en) 1987-05-14 1988-12-06 Inbae Yoon Plug for use in a reversible sterilization procedure
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
DE69428536T2 (de) 1993-07-13 2002-06-06 Nasa A3 -adenosin -rezeptor agonisten
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
AU1399297A (en) 1996-01-24 1997-08-20 Sumitomo Chemical Company, Limited Dihalopropene compounds, their use as insecticides/acaricides and intermediates for their production
AU730818B2 (en) * 1997-03-07 2001-03-15 Vernalis Research Limited Use of (+)mefloquine for the treatment of malaria
WO1999006053A1 (en) 1997-07-29 1999-02-11 Medco Research, Inc. N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
US6048865A (en) 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
US6329349B1 (en) 1997-10-23 2001-12-11 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid A and adenosine receptor agents
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
ATE292973T1 (de) * 2001-01-16 2005-04-15 Can Fite Biopharma Ltd Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation
IL157734A0 (en) * 2001-03-06 2004-03-28 Cellegy Pharma Inc Pharmaceutical compositions for the treatment of urogenital disorders
US20030143282A1 (en) * 2002-01-28 2003-07-31 Pnina Fishman Adenosine A3 receptor agonist
WO2004086034A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
WO2007045989A1 (en) * 2005-10-20 2007-04-26 Pfizer Limited Pyridyl derivatives useful as h3 ligands
JP2009514846A (ja) 2005-11-04 2009-04-09 ファイザー・リミテッド テトラヒドロナフチリジン誘導体
ES2360632T3 (es) * 2006-01-26 2011-06-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Moduladores alostéricos del receptor a3 de adenosina.
US20100254965A1 (en) * 2006-10-24 2010-10-07 Board Of Regents ,The University Of Texas System Adenosine Signaling in Diagnosis, Treatment, and Prevention of Priapism and Erectile Dysfunction
WO2009006089A2 (en) * 2007-06-29 2009-01-08 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A2 adenosine receptor agonists

Also Published As

Publication number Publication date
JP2015524465A (ja) 2015-08-24
MX2015001644A (es) 2015-08-14
EP3530273A3 (en) 2020-02-26
CA2880753C (en) 2019-09-10
EP2892533A1 (en) 2015-07-15
KR20150042232A (ko) 2015-04-20
BR112015002697A2 (pt) 2017-10-31
JP6140825B2 (ja) 2017-05-31
CN104619323B (zh) 2018-03-09
KR101971762B1 (ko) 2019-08-13
AU2013301125A1 (en) 2015-02-12
IL237107A0 (en) 2015-03-31
CA2880753A1 (en) 2014-02-13
US20150216889A1 (en) 2015-08-06
AU2013301125B2 (en) 2018-03-15
IL237107B (en) 2019-11-28
HK1209342A1 (en) 2016-04-01
US9549943B2 (en) 2017-01-24
EP3530273A2 (en) 2019-08-28
WO2014024195A1 (en) 2014-02-13
CN104619323A (zh) 2015-05-13
RU2015105407A (ru) 2016-10-10

Similar Documents

Publication Publication Date Title
CO6831975A2 (es) Inmunoconjugados, composiciones para prepararlos, métodos para prepararlos y uso
BR112015013440A2 (pt) composições compreendendo dinucleotídeos de purina cíclicos com estereoquímicas e métodos definidos para sua preparação e uso
CL2015000092A1 (es) Oligonucleótidos quiralmente controlados, composición que los comprende; método de elaboración: y uso para tratar cáncer.
BR112017015944A2 (pt) composições de oligossacarídeo para uso em ração animal e métodos para produzir as mesmas
SMT201500097B (it) Derivati di 4-amminopirimidina e loro uso come antagonsiti del recettore di adenosina a2a
CO6900118A2 (es) Métodos para tratar el cancer por el uso de antagonistas de unión al eje pd-1e inhibidores de mek
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
BR112012025101A2 (pt) compostos antagonistas seletivos de receptor nk-3, composição farmacêutica e métodos para uso em distúrbios mediados por receptores nk-3
BR112012002331A2 (pt) composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
CL2014003232A1 (es) Formulaciones y métodos para la administración vaginal de antiprogestinas.
BR112014014547A2 (pt) compostos antagonistas de e-selectina, composições e métodos de uso
CO7000778A2 (es) Derivados de pirazolopiridina, su procedimiento de preparación y su uso terapéutico
CO6970609A2 (es) Composición farmacéutica y métodos de uso de derivados de 4-pregenen-11ß-17-21-triol-3,20-diona
HK1220388A1 (zh) 尿苷核苷衍生物、組合物及使用方法
BR112013022883A2 (pt) aptâmero, composição farmacêutica, kit, uso de um aptâmero e coluna de aférese
BR112013033138A2 (pt) componente para absorver e/ou transmitir forças mecânicas e/ou momentos, método de produção e uso de componente
BR112015027026A2 (pt) composição para uso na redução da formação de crosta e na promoção da cicatrização
BR112012024996A2 (pt) uso de pelo menos um tiossulfinato ou tiossulfinato de tiossulfinato de dialquila para reduzir o número de apicompelox em um animal
CL2016000998A1 (es) Composición herbaria, procedimiento para su preparación y uso de la misma
BR112013004659A8 (pt) teobromina em combinação com um expectorante ou um mucolítico para uso em terapia
CL2014003185A1 (es) Preformulacion de baja viscosidad que comprende pasireotida, agonista del receptor de somatostatina; proceso de preparacion de la preformulacion; kit farmaceutico; uso para tratar enfermedad de cushing o acromegalia.
BR112014002272A2 (pt) bandagens baseadas em metal, termicamente condutoras para auxiliar na cura e métodos de uso
CL2013003435A1 (es) Proceso de preparacion de intermediarios de estetrol utilizando catalizadores de paladio y grupos protectores acilantes o sililantes; y uso de dicho proceso para preparar estetrol.
BR112015006960A2 (pt) uso de uma combinação, composição e método para preparar um produto de espuma
HK1203496A1 (en) Carbocyclic nucleosides and their pharmaceutical use and compositions

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]